#United States #New York #Securities Fraud #Pomerantz LLP #ADC Therapeutics

Pomerantz Law Firm Investigates Claims on Behalf of ADC Therapeutics Investors

Pomerantz LLP, a renowned law firm with a rich history in corporate and securities litigation, has launched an investigation concerning claims from investors of ADC Therapeutics SA. This inquiry focuses on whether the company and its officials may have engaged in any unlawful practices, including securities fraud.

Background of ADC Therapeutics SA

ADC Therapeutics, listed on the New York Stock Exchange under the ticker ADCT, is a biotechnology company known for its innovative research and developments in therapy for cancer. Recently, the company updated investors with new data from its clinical trial involving ZYNLONTA®, a treatment aimed at patients suffering from relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Clinical Trial and Disclosures

In a press release dated December 3, 2025, ADC Therapeutics reported positive preliminary data from the LOTIS-7 Phase 1b trial. The trial aimed to evaluate the effectiveness and safety of ZYNLONTA® in combination with another treatment, glofitamab (COLUMVI®). However, the announcement also revealed concerning findings, including significant adverse events in two trial participants, one of which appeared to be treatment-related. Moreover, it was noted that cytokine release syndrome occurred in nearly 37% of the trial participants across differing dosage levels.

This mixed feedback from the trial contributed to a significant downturn in ADC's stock price, which fell by 14.13% to close at $3.95 per share following the press release. This drop showcased the market's reaction to the disclosed potential risks associated with the treatment under evaluation.

Investor Advisory

In light of these developments, Pomerantz LLP advises affected investors to come forward and share their experiences. Danielle Peyton, an attorney from the firm, can be reached for inquiries regarding the investigation at [email protected] or by calling 646-581-9980, ext. 7980. The firm is keen on understanding the depth of potential wrongdoing or negligence by the company's leadership, as these issues may warrant further legal action.

Pomerantz's Role in Investor Rights

Pomerantz LLP has established itself as a pioneer in the realm of class action lawsuits related to corporate misconduct. Founded over 85 years ago by the visionary Abraham L. Pomerantz, the firm has consistently fought to recover losses for shareholders and investors impacted by securities fraud and corporate misbehavior. Their esteemed track record includes attaining substantial damages on behalf of class members affected by unethical practices.

With offices in major cities such as New York, Chicago, and London, Pomerantz continues to uphold its commitment to advocating for those who have suffered due to fraudulent activities or breaches of fiduciary duties within the corporate sector. Their ongoing investigation into ADC Therapeutics exemplifies their dedication to serving the interests of investors and holding companies accountable for transparent business practices.

Those interested in joining the collective action against ADC Therapeutics are encouraged to seek legal advice and stay updated on further developments from Pomerantz LLP as they delve deeper into this complex case. By fighting for the rights of victims of securities fraud, Pomerantz aims to ensure justice and restore lost confidence among investors and stakeholders alike.